1
|
Yao Y, Liu Z, Zhao M, Chen Z, Li P, Zhang Y, Wang Y, Zhao C, Long C, Chen X, Yang J. Design, synthesis and pharmacological evaluation of 4-(3-chloro-4-(3-cyclopropylthioureido)-2-fluorophenoxy)-7-methoxyquinoline-6-carboxamide (WXFL-152): a novel triple angiokinase inhibitor for cancer therapy. Acta Pharm Sin B 2020; 10:1453-1475. [PMID: 32963943 PMCID: PMC7488503 DOI: 10.1016/j.apsb.2020.04.002] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2019] [Revised: 03/18/2020] [Accepted: 03/26/2020] [Indexed: 02/05/2023] Open
Abstract
Angiokinases, such as vascular endothelial-, fibroblast- and platelet-derived growth factor receptors (VEGFRs, FGFRs and PDGFRs) play crucial roles in tumor angiogenesis. Anti-angiogenesis therapy using multi-angiokinase inhibitor has achieved great success in recent years. In this study, we presented the design, synthesis, target identification, molecular mechanism, pharmacodynamics (PD) and pharmacokinetics (PK) research of a novel triple-angiokinase inhibitor WXFL-152. WXFL-152, identified from a series of 4-oxyquinoline derivatives based on a structure-activity relationship study, inhibited the proliferation of vascular endothelial cells (ECs) and pericytes by blocking the angiokinase signals VEGF/VEGFR2, FGF/FGFRs and PDGF/PDGFRβ simultaneously in vitro. Significant anticancer effects of WXFL-152 were confirmed in multiple preclinical tumor xenograft models, including a patient-derived tumor xenograft (PDX) model. Pharmacokinetic studies of WXFL-152 demonstrated high favourable bioavailability with single-dose and continuous multi-dose by oral administration in rats and beagles. In conclusion, WXFL-152, which is currently in phase Ib clinical trials, is a novel and effective triple-angiokinase inhibitor with clear PD and PK in tumor therapy.
Collapse
Key Words
- ATCC, American Type Culture Collection
- AUC, area under the plasma concentration–time curve
- Anti-angiogenesis therapy
- CE, collision energy
- CL, systemic clearance
- Cmax, maximum plasma concentration
- Drug synthesis
- EC, vascular endothelial cell
- ECM, endothelial cell medium
- ERKs, extracellular signal-regulated kinases
- FGF, fibroblast growth factor
- FGFRs, fibroblast growth factor receptors
- HBVPs, human brain vascular pericytes
- HUVECs, human umbilical vein endothelial cells
- IC50, half maximal inhibitory concentration
- IHC, immunohistochemistry
- LC–MS, liquid chromatography mass spectrometry
- LLOQ, lower limit of quantification
- MRM, multiple reaction monitoring
- MsOH, methane sulfonic acid
- Multi-angiokinase inhibitor
- NMR, nuclear magnetic resonance
- PD, pharmacodynamics
- PDB, protein data bank
- PDGF, platelet-derived growth factor
- PDGFRs, platelet-derived growth factor receptors
- PDX, patient-derived tumor xenograft
- PK, pharmacokinetics
- PM, pericyte medium
- Pharmacokinetic
- QC, quality control
- RE, values and relative error
- RSD, relative standard deviation
- RTKs, receptor tyrosine kinases
- TGI, tumor growth inhibition rate
- TLC, thin-layer chromatography
- Tmax, time the maximum concentration occurred
- Tumor
- ULOQ, up limit of quantitation
- VEGF, vascular endothelial growth factor
- VEGFRs, vascular endothelial growth factor receptors
- Vdss, volume of distribution at steady state
- i.v., intravenous injection
- p.o., per os
Collapse
Affiliation(s)
- Yuqin Yao
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, China
- Guangdong Zhongsheng Pharmaceutical Co., Ltd., Dongguan 523325, China
- West China School of Public Health and West China Fourth Hospital, Healthy Food Evaluation Research Center, Sichuan University, Chengdu 610041, China
| | - Zhuowei Liu
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, China
- Guangdong Zhongsheng Pharmaceutical Co., Ltd., Dongguan 523325, China
- Guangdong Raynovent Biotech Co., Ltd. Dongguan 523325, China
| | - Manyu Zhao
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, China
- West China School of Public Health and West China Fourth Hospital, Healthy Food Evaluation Research Center, Sichuan University, Chengdu 610041, China
| | | | - Peng Li
- WuXi AppTec Ltd. Shanghai 200131, China
| | | | - Yuxi Wang
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, China
| | - Chengjian Zhao
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, China
| | - Chaofeng Long
- Guangdong Zhongsheng Pharmaceutical Co., Ltd., Dongguan 523325, China
- Guangdong Raynovent Biotech Co., Ltd. Dongguan 523325, China
| | - Xiaoxin Chen
- Guangdong Zhongsheng Pharmaceutical Co., Ltd., Dongguan 523325, China
- Guangdong Raynovent Biotech Co., Ltd. Dongguan 523325, China
| | - Jinliang Yang
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, China
- Guangdong Zhongsheng Pharmaceutical Co., Ltd., Dongguan 523325, China
- West China School of Public Health and West China Fourth Hospital, Healthy Food Evaluation Research Center, Sichuan University, Chengdu 610041, China
| |
Collapse
|